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Hepatic arterial infusion chemotherapy (HAIC) has been employed as an alternative 
therapy to sorafenib for the patients with advanced hepatocellular carcinoma (HCC). In 
this study, we performed a comparative analysis of various immune cell responses 
including tumor-associated antigen (TAA)-specific T cells, regulatory T cells (Tregs) 
and myeloid-derived suppressor cells (MDSCs) in advanced HCC patients treated with 
HAIC. Thirty-six HCC patients were examined in the study. Interferon gamma 
enzyme-linked immunospot assays were performed to examine the frequency of 
TAA-specific T cells. The frequencies of Tregs and MDSCs were examined by 
multicolor fluorescence-activated cell sorting analysis. The treatment with HAIC using 
interferon (IFN)/ 5-fluorouracil (FU) or IFN/FU + cisplatin modulated the frequencies 
of various immune cells. In 22.2% of patients, the frequency of TAA-specific T cells 
increased after HAIC. Although the frequency of Tregs decreased after HAIC, it was not 
associated with the prognosis of patients. An analysis of prognostic factors for overall 
survival identified diameter of the tumor (<3.0 cm), absence of major portal vein 
invasion, absence of distant metastasis, Union Internationale Contre Le Cancer tumor 
lymph node metastasis stage (I or II), neutrophil lymphocytic ratio (<2.1) and the 
frequency of MDSCs (<30.5%) as factors that prolonged overall survival time after 
HAIC. Even in the group adjusted with progressive levels of tumors, patients with a low 
frequency of MDSCs had a significantly longer overall survival time. In conclusion, the 
frequency of MDSCs before the treatment is a prognostic factor in HAIC against HCC. 
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Précis: Hepatic arterial infusion chemotherapy (HAIC) for hepatocellular carcinoma 
(HCC) modulates the frequencies of various immune cells. The frequency of MDSCs 
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Alphabetical list of Abbreviations 
 
AFP, alpha-fetoprotein 
BCLC, Barcelona clinic liver cancer 
CD, cluster of differentiation 
CMV, cytomegalovirus  
CR, complete response  
CTL, cytotoxic T lymphocyte  
ELISPOT, enzyme-linked immunospot  
FACS, fluorescence-activated cell sorter/sorting 
FCS, fetal calf serum  
FOXp3, forkhead box p3  
FU, fluorouracil  
HAIC, hepatic arterial infusion chemotherapy  
HBV, hepatitis B virus  
HBsAg, hepatitis B virus surface antigen  
HCC, hepatocellular carcinoma 
HCV, hepatitis C virus  
HCVAb, hepatitis C virus antibody  
HIV, human immunodeficiency virus  
HLA, human histocompatibility leukocyte antigen 
HPLC, high performance liquid chromatography  
IFN, interferon 
IL, interleukin 
MDSC, myeloid-derived suppressor cell 
NLR, neutrophil lymphocytic ratio  
PBMC, peripheral blood mononuclear cell  
PBS, phosphate-buffered saline 
PD, progressive disease  
PD-L1, programmed death ligand 1  
PMA, phorbol myristate acetate 
PR, partial response  
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RFA, radiofrequency ablation  
RPMI, Roswell Park Memorial Institute (culture medium) 
SD, stable disease  
TAA, tumor-associated antigen 
TACE, transarterial chemoembolization 
TGF, transforming growth factor  
TNM, tumor lymph node metastasis stage 
Treg, regulatory T cell  
UICC, Union Internationale Contre Le Cancer  
 





 Hepatocellular carcinoma (HCC) is the most common primary malignancy of the 
liver and remains an important public health concern because its incidence has 
continued to increase globally [2]. Many different kinds of approaches, such as surgical 
resection, liver transplantation, radiofrequency ablation (RFA), transarterial 
chemoembolization (TACE), chemotherapy, and sorafenib, are performed according to 
practical guidelines for the treatment of HCC [3]; however, their effects are limited and 
the recurrence rate of HCC remains very high [4]. Moreover, patients who have already 
developed HCC are mostly in an advanced stage at the time of diagnosis and, as such, 
the efficacy of surgical resection, RFA, and TACE is limited for such cases. Although 
sorafenib has been shown to have a significant survival benefit in several large-scale 
clinical trials and has been established as the standard treatment for advanced HCC [5], 
its efficacy and tolerability are also limited [6]. Hepatic arterial infusion chemotherapy 
(HAIC) has been employed as an alternative therapy to sorafenib in Japan and other 
Asian countries [7, 8]. 
 The modulation of tumor-associated host immune responses after cancer treatments 
has recently been reported. For example, HCC treatments with RFA or TACE were 
found to increase the frequency of tumor-associated antigen (TAA)-specific T cells due 
to the creation of an antigen source by the destruction of tumor cells [9, 10]. In addition, 
recent studies demonstrated that beyond their direct cytotoxic effects on cancer cells, 
several conventional chemotherapeutic drugs promoted the elimination or inactivation 
of regulatory T cells (Tregs) or myeloid-derived suppressor cells (MDSCs), resulting in 
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enhanced host antitumor immunity [11, 12]. These findings support the 
immunotherapeutic effects of HAIC for HCC. However, the effects of HAIC on host 
immune responses and the relationship between the prognosis of patients treated with 
HAIC and host immune responses remain unclear. 
 In the present study, we performed a comparative analysis of various immune cell 
responses including TAA-specific T cells, Tregs, and MDSCs in advanced HCC patients 
treated with HAIC.  
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MATERIALS AND METHODS 
 
Patients and laboratory testing 
 Thirty-six human histocompatibility leukocyte antigen (HLA)-A24-positive 
patients who had clinically diagnosed HCC were examined in the present study (Table 
1). HCC was diagnosed based on underlying chronic liver disease, radiological findings, 
and elevations in tumor markers. Regarding the tumor stage, the following patients were 
included: patients who had (1) severe vascular invasion (i.e. vascular invasion in the 
main trunk to the secondary branches of the portal vein, or invasion in the right, middle, 
or left hepatic vein) and (2) multiple intrahepatic lesions (i.e. 5 or more nodules in the 
left and/or right lobes as confirmed by radiology). After being diagnosed, all patients 
were treated with HAIC using interferon (IFN)/ 5-fluorouracil (FU) or IFN/FU + 
cisplatin at Kanazawa University Hospital between October 2003 and September 2007. 
All of the patients in this study were first line patients. In the IFN/FU treatment group, 
patients received a continuous hepatic arterial infusion of FU (5-FU, Kyowa Hakko, 
Tokyo, Japan) at a dose of 300 mg/m2 /day for 5 days in the 1st and 2nd weeks (for 120 
h) using an infuser pump (Baxter Infusor SV1, Tokyo, Japan) as described previously 
[13]. The maximum amount of FU infused over 5 days was 2,500 mg. IFN α-2b (Intron 
A, Schering-Plough, Osaka, Japan) at a dose of 3,000,000 units was injected 
intramuscularly 3 times a week for 4 weeks. In the IFN/FU + cisplatin treatment group, 
cisplatin (Randa, Nippon Kayaku, Tokyo, Japan) at a dose of 20 mg/m2 was given by a 
hepatic arterial infusion over 1.5 h on days 1 and 8 prior to the administration of FU and 
after appropriate hydration and antiemetic medication. A treatment cycle comprised 4 
weeks of drug administration including the administration of IFN and a subsequent 
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2-week rest period. 
 The response rate after HAIC was determined using dynamic computed 
tomography or magnetic resonance imaging performed at the end of each treatment 
cycle according to the Response Evaluation Criteria in Solid Tumors, version 1.1 [14]. 
The overall survival time was defined as the period from the time of beginning of 
treatment until death, and the progression-free survival time was defined as the period 
from the beginning of the treatment until the confirmation of progression or death. 
 Blood samples were tested for hepatitis B virus surface antigen (HBsAg) and 
hepatitis C virus antibody (HCVAb) using commercial immunoassays (Fuji Rebio, 
Tokyo, Japan). The HLA-based typing of peripheral blood mononuclear cells (PBMCs) 
from patients and normal blood donors was performed as described previously [15]. 
Serum alpha-fetoprotein (AFP) levels were measured by an enzyme immunoassay 
(AxSYM AFP, Abbott Japan, Tokyo, Japan).  
 All patients provided written informed consent to participate in the study in 
accordance with the Helsinki Declaration and this study was approved by the regional 
Ethics Committee (Medical Ethics Committee of Kanazawa University, No. 5169). 
 
Peptides and preparation of PBMCs 
 Eleven peptides derived from 5 different TAAs (Supplementary Table 1) [10], a 
human immunodeficiency virus (HIV) envelope-derived peptide (HIVenv584) [16], and 
cytomegalovirus (CMV) pp65-derived peptide (CMVpp65328) [17], which were 
previously identified as HLA-A24-restricted cytotoxic T lymphocyte (CTL) epitopes 
were used. Peptides were synthesized at Sumitomo Pharmaceuticals (Osaka, Japan).  
They were identified using mass spectrometry, and their purities were determined to be 
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>90% by analytical high performance liquid chromatography (HPLC). PBMCs were 
isolated before and 2-4 weeks after starting HAIC as described below; heparinized 
venous blood was diluted in phosphate-buffered saline (PBS) and loaded on 
Ficoll-Histopaque (Sigma, St. Louis, Mo.) in 50-ml tubes. After centrifugation at 2000 
rpm for 20 min at room temperature, PBMCs were harvested from interphase, 
resuspended in PBS, centrifuged at 1400 rpm for 10min, and then resuspended in 
complete culture medium consisting of Roswell Park Memorial Institute (RPMI) culture 
medium (GibcoBRL, Grand Island, NY), 10% heat inactivated fetal calf serum (FCS) 
(Gibco BRL), 100 U/ml penicillin, and 100 μg/ml streptomycin (Gibco BRL). PBMCs 
were resuspended in RPMI 1640 medium containing 80% FCS and 10% dimethyl 
sulfoxide, and cryopreserved until use. 
 
IFN-γ ELISPOT assay 
 IFN-γ enzyme-linked immunospot (ELISPOT) assays were performed as reported 
previously [18]. Negative controls consisted of a HIV envelope-derived peptide 
(HIVenv584) [16]. Positive controls consisted of 10 ng/ml phorbol 12-myristate 
13-acetate (PMA, Sigma) or a CMV pp65-derived peptide (CMVpp65328) [17]. The 
amino acid sequences of all peptides are shown in Supplementary Table 1. The colored 
spots were counted with a KS ELISpot Reader (Zeiss, Tokyo, Japan). The number of 
specific spots was determined by subtracting the number of spots in the absence of an 
antigen from the number in its presence. Responses to TAA-derived peptides were 
considered positive if more than 10 specific spots were detected, which is greater than 
the mean plus 3 standard deviation of the baseline response detected in 11 normal blood 
donors (Supplementary Table 1), and if the number of spots in the presence of an 
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antigen was at least twofold that in its absence. Responses to HIV- and CMV-derived 
peptides were considered positive if more than 10 specific spots were detected and if the 
number of spots in the presence of an antigen was at least twofold that in its absence.  
 
Flow cytometric analysis 
 A multicolor fluorescence-activated cell sorting analysis was carried out using the 
Becton Dickinson FACSAria II system to determine the frequency and phenotype of 
Tregs and MDSCs. The following anti-human monoclonal antibodies were used: 
anti-cluster of differentiation (CD)4 (Becton Dickinson), anti-CD11b (Becton 
Dickinson), anti-CD14 (Becton Dickinson), anti-CD15 (Becton Dickinson), anti-CD25 
(Becton Dickinson), anti-CD33 (Becton Dickinson), anti-forkhead box p3 (FOXp3) 
(Becton Dickinson), anti-CD127 (Becton Dickinson), anti-programmed death ligand 1 




Cytokine levels in serum were measured using the ProcartaⓇCytokine Assay 
(Affymetrix, Santa Clara, CA) as previously reported [19]. These included interleukin 
(IL)-2, IL-4, IL-6, IL-8, IL-10 and transforming growth factor (TGF)-β1. Data 




Data are expressed as means ± standard deviation. The chi-squared test with Yates’ 
correction, paired t-test, and unpaired t-test were used for statistical analyses where 
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appropriate. The probabilities of overall survival were estimated using the 
Kaplan-Meier method. The Mantel-Cox log-rank test was used to compare curves 
between groups. The prognostic factors for overall survival were analyzed for 
significance by the Kaplan–Meier method (univariate). A level of p<0.05 was 
considered significant.  






 The clinical profiles of the 36 patients with advanced HCC who participated in the 
present study are shown in Table 1. Major portal vein invasion, lymph node metastasis, 
and distant metastasis were noted in 15, 1, and 3 patients, respectively. Using Barcelona 
clinic liver cancer (BCLC) TNM staging, 19, 15, and 2 patients were classified as stage 
B, C, and D, respectively. Using TNM staging of the Union Internationale Contre Le 
Cancer (UICC) system (6th version), 4, 29, and 3 patients were classified as stage II, III 
and IV, respectively. Thirty patients had liver cirrhosis and 16, 18, and 2 patients were 
classified as grade A, B, and C according to the Child-Pugh classification. Among the 
36 patients, the best study response was a complete response (CR) in 1 (2.8%) patient; a 
partial response (PR) was observed in 18 (50.0%) patients, stable disease (SD) was 
observed in 6 (16.7%) patients, and progressive disease (PD) was observed in 11 
(30.6%) patients. 
 
Detection of TAA-specific T cells  
 The detection of TAA-specific T cells was performed by a direct ex-vivo analysis 
(IFN-γ ELISPOT assay). The cut-off of positivity was set at ≥10 specific spots/300,000 
PBMCs (see Materials and Methods). We examined the frequency of cells that 
specifically reacted with TAA-derived and control peptides using PBMCs obtained 
before the treatment with HAIC. Nineteen responses were observed against 
TAA-derived peptides. Eleven out of 36 (30.6%) patients showed positive responses to 
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at least one TAA-derived peptide, while most showed responses to 1-3 kinds of 
TAA-derived peptide. The magnitude of TAA-specific T cell responses was assessed by 
the frequency of peptide-specific IFN-γ-producing T cells in the PBMC population. The 
range of the TAA-derived peptide-specific T cell frequency was 10.0-67.0 cells/300,000 
PBMCs. The frequencies of T cells specific to CMV-derived peptides were 10.0-299.5 
cells/300,000 PBMCs, respectively. 
 We performed the same analysis using PBMCs obtained 2-4 weeks after starting 
HAIC. When T cell responses against a single peptide with more than or equal to 10 
specific spots and a 2-fold increase were defined as significant, the number of patients 
who showed a significant increase against at least one TAA-derived peptide after HAIC 
was 8 (22.2%). However, no significant differences were observed in the frequency of 
patients who specifically reacted with TAA-derived and control peptides after the 
treatment (Supplementary Table 1).  
 
Detection of Tregs and MDSCs 
 We examined the frequency of Tregs and MDSCs in peripheral blood in order to 
identify the effects of HAIC on immune suppressor cells. The population of Tregs was 
detected as CD4+ CD25+ CD127-/low cells as previously reported (Fig. 1a) [20]. We also 
confirmed that this population was highly positive for CD25 and FOXp3. The frequency 
of Tregs varied greatly (1.9 to 12.1%) in HCC patients before HAIC and was 
significantly decreased after the treatment (p=0.043) (Fig. 1b).  
 Human MDSCs are classified to CD14-CD11b+CD33+CD15+ and CD14+HLA-DR- 
cells [21]. In the present study, we identified both fractions in PBMCs of HCC patients 
and focused in CD14+HLA-DR- phenotype because the recent studies have shown that 
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the frequency of MDSCs with CD14+HLA-DR- phenotype is increased in HCC patients 
(Fig. 1c) [20]. CD14+HLA-DR- and CD14-CD11b+CD33+CD15+ MDSCs showed low 
expression of PD-L1 before treatment. The fraction of CD14+HLA-DR-/low detected in 
this study showed 2 cell populations with low and high PD-L1 expression. After HAIC 
treatment, the expression levels of PD-L1 in CD14+HLA-DR- MDSCs were increased in 
most of the patients examined (Supplementary Fig. 1b and c). The CD14+HLA-DR-/low 
population in the PBMCs of HCC patients represented 10.5% to 71.3% of CD14+cells 
before HAIC. In contrast to Tregs, no significant differences were observed in the 
frequency of MDSCs after HAIC (p=0.609) (Fig. 1d). We observed a decrease in serum 
TGF-β1 concentration after HAIC (Supplementary Fig. 1a). The concentrations of other 
cytokines did not change with statistical significance before and after the treatment. 
 
Identification of host factors related to the frequencies of Tregs and MDSCs  
 To identify host factors related to the frequencies of Tregs and MDSCs, we 
compared the frequencies of these immune suppressor cells with various clinical factors. 
Although the frequency of circulating Tregs is known to correlate with disease 
progression in cancer patients, the frequency of CD4+ CD25+ CD127-/low Tregs did not 
correlate with the status of tumor progression, which consisted of the UICC stage, 
BCLC stage, diameter of the tumor, major portal vein invasion, and distant metastasis as 
well as other clinical factors (Fig. 2a). 
 In contrast to Tregs, the frequency of MDSCs was associated with these tumor 
factors. Patients with the advanced UICC stage, a large tumor diameter, major portal 
vein invasion, and distant metastasis of HCC showed a high frequency of MDSCs in 
peripheral blood (Fig. 2b). Patients with a high neutrophil to lymphocyte ratio (NLR), 
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which has been suggested to be associated with the outcomes of patients with various 
malignancies [22, 23], also showed a high frequency of MDSCs.  
 
Patient outcomes and frequencies of Tregs and MDSCs  
 We examined the relationship between patient outcomes and the frequencies of 
Tregs and MDSCs. Patients were divided into two groups: patients with CR or PR and 
those with SD or PD, and the frequencies of Tregs and MDSCs were compared between 
these groups before and after the treatment. No significant differences were observed in 
the frequency of Tregs between these groups before and after the treatment (Fig. 3a and 
b). In contrast, the frequency of MDSCs was significantly lower in the group with CR 
or PR before the treatment than in the group with SD or PD (p=0.006) (Fig. 3c). Similar 
results were also obtained in the analysis of MDSCs after the treatment (p=0.043) (Fig. 
3d). 
 
Effects of immune cells on the prognosis of patients treated with HAIC 
 To determine the effects of various immune cells on the prognosis of HCC patients 
treated with HAIC, we analyzed the relationship between the frequencies of immune 
cells, consisting of TAA-specific T cells, Tregs, and MDSCs, before the treatment and 
overall survival after HAIC. To analyze TAA-specific T cells, we divided patients into 
two groups: those with high (above median) and low (below median) specific spots as 
detected by the ELISPOT assay. We did not find any associations between the frequency 
of TAA-specific T cells, which was calculated as a total number of T cells detected by 
IFN-γ ELISPOT assay using 11 TAA-derived peptides (Supplementary Table 1), and 
overall survival after HAIC (Fig. 4a). The frequency of Tregs before the treatment was 
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also not associated with the overall survival of patients treated with HAIC (Fig. 4b). In 
contrast, the overall survival of patients with a high frequency of MDSCs before the 
treatment was significantly shortened (p=0.003) (Fig. 4c). The difference between the 
groups was emphasized when 40% was defined as high (p<0.001) (Fig. 4d). 
A univariate analysis of prognostic factors for overall survival identified NLR (<2.1), 
diameter of the tumor (<3.0 cm), absence of major portal vein invasion, absence of 
distant metastasis, BCLC TNM stage (A or B), UICC TNM stage (I or II), and the 
frequency of MDSCs (<30.5%) as factors that prolonged the overall survival time after 
HAIC (Table 2). Since the number of patients was insufficient for a multivariate 
analysis of prognostic factors for overall survival and the frequency of MDSCs was 
associated with the progression of tumors, as shown in Figure 4e, we examined the 
relationship between the frequency of MDSCs and overall survival after HAIC in a 
limited patient group with only UICC TNM stage II or III. Even in the group adjusted 
with progressive levels of tumors, patients with a low frequency of MDSCs had a 
significantly longer overall survival time (p=0.010) (Fig. 4e).





 Increases have been reported in the frequency of TAA-specific T cells after 
treatments for HCC such as RFA and TACE [9, 10]. In the present study, we found an 
increase in the frequency of TAA-specific T cells after HAIC in a very limited number 
of patients, which was unexpected. The 36 patients evaluated in this study included 19 
who showed CR or PR to the treatment and decreases in the tumor size. However, an 
analysis of changes in the frequency of T cells specific to each epitope revealed  
increases in only 4 out of the 19 patients. This result suggested that HAIC using 
cisplatin and 5FU induced necrosis or apoptosis in tumor tissue, but was not appropriate 
for inducing anti-tumor immunity, unlike RFA and TACE. 
 Recent studies reported that anti-tumor chemotherapy produced its anti-tumor 
effects by not only direct cytotoxic effects against tumor cells, but also the elimination 
or inactivation of cells with suppressive effects on tumor immunity such as Tregs and 
MDSCs [11, 12]. In the present study, the frequency of Tregs also decreased after the 
treatment, which was consistent with the previously reported responses of Tregs to 
chemotherapy against colon cancer using cyclophosphamide and non-small cell lung 
cancer using paclitaxel [24, 25]. The decrease was more prominent in patients with the 
higher frequency of Tregs pretreatment, suggesting the treatment might be more 
effective in such patients. However, the decrease observed in the number of Tregs did 
not appear to contribute to the increase in the frequency of TAA-specific T cells.  
No significant changes were observed in the frequency of MDSCs after the 
treatment. The chemotherapy evaluated in this study included 5FU, which has been 
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reported to reduce the frequency of MDSCs in peripheral blood in mouse thymoma and 
colorectal cancer models and humans with colorectal cancer [26, 27]. Similar results 
were not obtained in the present study using 5FU presumably because of the difference 
in its administration route, which was via the hepatic artery. Previous studies on the 
pharmacokinetics of 5FU reported that the concentration of 5FU in peripheral blood 
was lower by an administration route via the hepatic artery than by an intravenous 
administration route [28], and this is considered to have been a reason for the failure in 
this study to reduce the frequency of MDSCs. There was no statistically significant 
difference between the patients treated with IFN/5FU and IFN/5FU + cisplatin 
regarding the clinical data and the frequency of TAA-specific T cells, Tregs and MDSCs 
before and after the treatment. 
We previously reported that the frequency of MDSCs decreased after RFA, a standard 
treatment for HCC, and also that the number of TAA-specific T cells after this treatment 
negatively correlated with the frequency of MDSCs [10]. In this study, in 8 patients 
showing increased TAA-specific T cell responses to at least one TAA-derived peptide 
after HAIC, 3 and 2 patients showed a decreasing of number of Tregs and MDSCs, 
respectively. Although the absence of an increase in the number of TAA-specific T cells 
after chemotherapy in the present study might be related to a failure in the induction of a 
decrease in the frequency of MDSCs by the treatment, the relationship should be further 
studied. In addition, one of the limitations of this study is that the function of Tregs and 
MDSCs has not been investigated. It also should be further studied. 
 An analysis of the relationships between TAA-specific T cells, Tregs, and MDSCs 
and the therapeutic effects observed revealed that the frequency of MDSCs before the 
treatment was significantly lower in the patients that showed CR or PR to HAIC than in 
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those showed SD or PD. No significant difference was observed in the frequency of 
TAA-specific T cells or Tregs before the treatment and the frequency of these 3 kinds of 
cells after the beginning of the treatment. Furthermore, an analysis of patient outcomes 
after the treatment showed a longer overall survival period in patients with a lower 
frequency of MDSCs before the treatment. These results were consistent with previous 
findings in many cancer types [29] and suggested that the frequency of MDSCs is an 
important prognostic factor in HCC patients undergoing HAIC. 
 Regarding host factors that affect the frequency of MDSCs, the degree of tumor 
progression indicated by the UICC stage, BCLC stage, diameter of the tumor, major 
portal vein invasion, and distant metastasis correlated with a high frequency of MDSCs, 
i.e., the frequency of MDSCs increased in patients with more advanced disease. 
Furthermore, a univariate analysis of factors contributing to overall survival identified a 
low frequency of MDSCs, low UICC or BCLC stage, tumors with small diameters, and 
the absence of major portal vein invasion and distant metastasis as significant factors. 
Since a multivariate analysis was not performed in this study due to the lack of a 
sufficient number of patients, it currently remains unknown whether the frequency of 
MDSCs influenced patient outcomes directly via immunological mechanisms or 
indirectly by reflecting the degree of tumor progression. Therefore, in order to elucidate 
the relationship between the frequency of MDSCs and patient outcomes in greater detail, 
we examined the relationship between the frequency of MDSCs and overall survival in 
UICC stage II or III patients. In this analysis, the overall survival was significantly 
longer in the group with a lower frequency of MDSCs even with standardization of the 
disease stage, suggesting that the frequency of MDSCs was an independent factor 
contributing to overall survival. Moreover, we recently reported a higher recurrence-free 
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survival rate and longer overall survival in patients with a low NLR before the treatment 
and suggested that the NLR was a prognostic factor in HAIC [30]. The frequency of 
MDSCs was lower in patients with a low NLR, suggesting that they are related. A 
review of the literature revealed that the relationship between MDSCs and the NLR has 
not yet been directly demonstrated, the NLR in HCC has been shown to reflect systemic 
or intratumoral micro-environmental inflammatory responses and correlated with 
intratumoral or systemic IL-17 concentrations [31]. Since MDSCs are induced by 
systemic inflammatory responses and are related to Th17 cell differentiation [32], an 
increase in the NLR has been suggested to be caused by an increase in MDSCs or the 
cytokines produced by them. These results also indicate that MDSCs are related to 
patient outcomes by some immunological mechanism. 
 In conclusion, this study showed that the frequency of MDSCs before the treatment 
was a prognostic factor in HAIC against HCC. The results of this study, which suggest 
that the frequency of MDSCs is a good clinical marker for the selection of patients 
treated with HAIC and the effectiveness of HAIC could be enhanced by controlling the 
frequency of MDSCs before the treatment, provide a useful insight into devising 
therapeutic strategies against HCC. The patients with high frequency of MDSCs before 
treatment might be better to be treated with another chemotherapeutic agents or 
sorafenib. 
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Figure 1: Frequencies of Tregs and MDSCs in peripheral blood of HCC patients before 
and 2-4 weeks after starting HAIC. (a) Gating strategy of CD4+ CD25+ CD127-/low 
Tregs. CD4+ CD25+ CD127-/low Tregs highly expressed the CD25 molecule and FOXp3 
(lower panels). (b) The frequency of Tregs before HAIC was compared with that 2-4 
weeks after starting HAIC. Percentages represent the proportions of CD4+ CD25+ 
CD127-/low Tregs among CD4+ cells. The frequency of Tregs varied greatly (1.9 to 
12.1%) in HCC patients before HAIC and significantly decreased after the treatment 
(p=0.043). (c) Gating strategies of CD14+HLA-DR- and CD14-CD11b+CD33+CD15+ 
MDSCs. The expression levels of PD-L1 on CD14+HLA-DR- and 
CD14-CD11b+CD33+CD15+ MDSCs (red lines) were examined by FACS analysis. Blue 
lines show the results using isotype antibody. (d) The frequency of MDSCs did not 
significantly change after HAIC. Percentages represent the proportions of 
CD14+HLA-DR-/low MDSCs among CD14+ cells. 
 
Figure 2: An analysis of tumor factors related to the frequencies of Tregs and MDSCs. 
Percentages represent the proportions of Tregs and CD14+HLA-DR-/low MDSCs among 
CD4+ and CD14+ cells, respectively. (a) The frequency of Tregs detected by flow 
cytometry before HAIC did not change with the status of tumors or any clinical factors. 
(b) The frequency of MDSCs correlated with tumor progression and NLR. 
 
Figure 3: An analysis of patient outcomes and frequencies of Tregs and MDSCs. 
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Patients were divided into two groups: patients with CR or PR and those with SD or PD, 
according to the Response Evaluation Criteria in Solid Tumors, version 1.1. (a) An 
analysis of patient outcomes and the frequency of Tregs before HAIC. (b) An analysis 
of patient outcomes and the frequency of Tregs after starting HAIC. (c) An analysis of 
patient outcomes and the frequency of MDSCs before HAIC. (d) An analysis of patient 
outcomes and the frequency of MDSCs after starting HAIC. 
 
Figure 4: Kaplan-Meier curves of overall survival. (a) Kaplan-Meier curves indicating 
the relationship between time after starting HAIC and the overall survival rate were 
grouped by the median number of TAA-specific T cells (indicated as CTLs) before 
HAIC. The number of TAA-specific T cells was calculated as a total number of T cells 
detected by IFN-γ ELISPOT assay using 11 TAA-derived peptides shown in 
supplementary table 1. (b) Kaplan-Meier curves indicating the relationship between 
time after starting HAIC and the overall survival rate were grouped by the median of the 
frequency of Tregs detected by flow cytometry before HAIC. (c) Kaplan-Meier curves 
indicating the relationship between time after starting HAIC and the overall survival 
rate were grouped by the median of the frequency of MDSCs detected by flow 
cytometry before HAIC. (d) The difference between the groups was emphasized when 
40 % was defined as a high frequency of MDSCs. (e) Kaplan-Meier curves of overall 
survival in HCC patients with stage 2 or 3 according to the UICC TNM classification. 
Kaplan-Meier curves indicating the relationship between time after starting HAIC and 
the overall survival rate were grouped by the frequency of MDSCs detected by flow 




Table 1 Characteristics of patients with HCC  
 n=36 Median 
Age (years)  62.7±8.5 62.5 
Sex (M/F) 32/4  




HCV-Ab (positive/negative) 21/15  
HBsAg (positive/negative) 13/23  
   Platelet count (X104/µl) 11.7±6.2 11.1 
ALT (IU/L) 46.2±26.3 38.5 
Active prothrombin (%) 76.9±16.6 76.0 
Albumin (g/dl) 3.5±0.4 3.5 
Total bilirubin (mg/dl) 1.3±0.9 0.9 
AFP (ng/ml) 13538.7±42742.1 501.0 
Diameter of the main tumor (mm) 47.7±44.8 30.0 
Major portal vein invasion (+/-) 15/21  
Lymph node metastasis (+/-) 1/35  
Distant metastasis (+/-) 3/33  
BCLC TNM stage (A/B/C/D) 0/19/15/2  
UICC TNM stage (I/II/III/IV) 0/4/29/3  
Liver cirrhosis (+/-) 30/6  
Liver function (Child A/B/C) 16/18/2  
Best study response (CR/PR/SD/PD) 1/18/6/11  
Values represent the numbers of patients or mean ± SD. ECOG = Eastern Cooperative 
Oncology Group; IFN = interferon; PS = performance status; ALT = alanine 
aminotransferase; AFP = alpha-fetoprotein; Major portal vein invasion = tumor invasion 
in the main trunk of the 1st branches of the portal vein; BCLC = Barcelona Clinic Liver 









Gender (male/female) 0.714 
Age (<62.5/62.5≤) 0.339 
HCV-Ab (+/-) 0.339 
HBsAg (+/-) 0.370 
Liver cirrhosis (+/-) 0.819 
Child-Pugh class (A/B, C) 0.816 
AST (<65.0/65.0≤ IU/L) 0.207 
ALT (<38.5/38.5≤ IU/L) 0.952 
Alb (<3.4/3.4≤ g/dL) 0.180 
T-bil. (<0.9/0.9≤ mg/dL) 0.515 
NLR (<2.1/2.1≤ ) 0.014 
Active prothrombin (<76/76≤ %) 0.208 
DCP (<241/241≤ mAU/mL) 0.833 
AFP (<501/501≤ ng/mL) 0.224 
Diameter of the tumor (<3.0/3.0≤ cm) 0.008 
Major portal vein invasion (+/-) 0.032 
Distant metastasis (+/-) 0.038 
BCLC TNM stage (A,B/C,D) 0.011 
UICC TNM stage (I,II/III,IV) 0.015 
TAA-specific T cells (<18.3/18.3≤)* 0.269 
Tregs (<6.4/6.4≤ %) 0.879 
MDSCs (<30.5/30.5≤ %) 0.009 
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Supplementary Table 1  Peptides and response frequencies 
Peptide  
name 
Amino acid  
sequences 
Number of specific  
spots in normal donors 
 (mean ± SD) 
Frequency of 
patients with 











SART2899 SYTRLFLIL 1.0±1.4 1/36 (2.8%) 2/36 (5.6%) >0.999 
SART3109 VYDYNCHVDL 2.1±1.9 2/36 (5.6%) 2/36 (5.6%) >0.999 
MRP3503 LYAWEPSFL 0.2±0.5 1/36 (2.8%) 0/36 (0%) >0.999 
MRP3692 AYVPQQAWI 1.5±2.1 1/36 (2.8%) 0/36 (0%) >0.999 
MRP3765 VYSDADIFL 0.9±1.0 2/36 (5.6%) 2/36 (5.6%) >0.999 
AFP357 EYSRRHPQL 1.8±2.0 3/36 (8.3%) 1/36 (2.8%) 0.614 
AFP403 KYIQESQAL 1.1±1.5 1/36 (2.8%) 1/36 (2.8%) >0.999 
AFP434 AYTKKAPQL 0.8±1.1 4/36 (11.1%) 3/36 (8.3%) >0.999 
hTERT167 AYQVCGPPL 0.8±1.1 1/36 (2.8%) 1/36 (2.8%) >0.999 
hTERT324 VYAETKHFL 0.5±0.7 3/36 (8.3%) 5/36 (13.9%) 0.710 
hTERT461 VYGFVRACL 0.7±1.2 0/36 (0.0%) 3/36 (8.3%) 0.239 
HIV env584 RYLRDQQLL 1.3±2.0 1/36 (2.8%) 0/36 (0%) >0.999 












































Supplementary Figure 1: (a) Concentrations of TGF-b1 in serum before and after 
HAIC. (b) The representative data of PD-L1 expression on CD14+HLA-DR- MDSCs 
before (blue line) and after (red line) HAIC. (c) The expression levels of PD-L1 on 
CD14+HLA-DR- MDSCs before and after HAIC. 
 
